Stelexis Therapeutics LLC, of New York, said it closed a $43 million series A financing. The company's drug discovery platform identifies the earliest definable pre-cancerous stem and progenitor cells that lead to the formation of human primary and recurrent tumors for therapeutic intervention and relapse prevention. The funding will support the delivery of clinical trial data and the validation of its platform.